MARKET NEWS

Orchard Therapeutics Announces $150-Million Financing to Advance Pipeline
Stemline Therapeutics Announces FDA Accepts ELZONRIS BLA & Grants Priority Review
MeiraGTx Announces AAV-CNGA3 Has Received Orphan Drug Designation
Mustang Bio & St. Jude Children’s Research Hospital Enter Exclusive Worldwide License Agreement
CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma
Aegis Awarded US Patent for Formulation & Non-invasive Delivery of Peptide Drugs

  FEATURED EDITORIAL

  COMPANY PROFILE

Catalent ODT/Fast DissolveCatalent is the leading global provider of advanced drug delivery technologies and development solutions, providing worldwide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. With over 80 years serving the industry, we have proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable product supply. We serve over 1,000 innovator customers – both established and emerging – in over 80 markets, including 85 of the top 100 branded drug marketers, 23 of the top 25 generics marketers, 23 of the top 25 biologics marketers, and 22 of the top 25 consumer health marketers globally. Each year, Catalent manufactures more than 72 billion units of nearly 7,000 products, which equates to approximately 1 in 20 doses taken each year by patients or consumers. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Sol-Gel Technologies Announces Collaborative Agreement With Perrigo

Sol-Gel Technologies Announces Collaborative Agreement With Perrigo

Sol-Gel Technologies Ltd. recently announced it has entered into a collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing, and commercialization of a generic product candidate.

Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial

Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial

Clementia Pharmaceuticals Inc.recently announced the early completion of patient enrollment in the MOVE Trial, Clementia’s registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP).

Credence Injection Delivery Devices

Credence MedSystems Closes $12.8-Million Financing to Support Ongoing Development & Scaling of Innovative Delivery Products

Credence MedSystems, Inc., an innovator in injectable drug delivery devices, recently announced the closing of a Series B financing resulting in gross proceeds to the company of $12.8 million.

Drug Devices

Nevakar & Endo Enter Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products

Nevakar Inc. recently announced it entered into an exclusive licensing agreement with Endo International plc’s subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the US and Canada.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

AUG 29 Transdermal/Topical Delivery
SEPT 5 Drug Delivery
SEPT 12 Injection Devices
SEPT 19 Lyophilization Manufacturing